The anti-tumor efficacy of TIL, both as monotherapy and in combination with the PD-1 inhibitor Nivolumab, was assessed against BCa cell lines and autologous PDO through viability (ATP), cytokine release (IFN-γ, ELISA), and apoptosis (caspase 3/7) assays. Here, IFNG is linked to neoplasm.